Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2022-03-18 00:00:00 ET · period of report 2021-07-15 · accession 0001179110-22-002328 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-18 | 2022-03-16 | KNSA | Moat Ross | Chief Commercial Off | F - Tax | $10.13 | -544 | 6,342 | -8% | -$5,511 |
| D | 2022-03-18 | 2022-03-16 | KNSA | Moat Ross | Chief Commercial Off | M - OptEx | — | +995 | 6,886 | +17% | — |
| DM | 2022-03-18 | 2021-07-15+ | KNSA | Moat Ross | Chief Commercial Off | A - Grant | $10.34 | +2,509 | 5,891 | +74% | +$26.0K |
| D | 2022-03-18 | 2022-03-16 | KNSA | Moat Ross | Chief Commercial Off | M - OptEx | $0.00 | -995 | 2,982 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Share | 2022-03-16 | F | D | 544 | $10.13 | 6,342 | D | — | — | |
| 2 | Common | Class A Common Share | 2022-03-16 | M | A | 995 | — | 6,886 | D | — | — | (F3) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. |
| 3 | Common | Class A Common Share | 2021-07-15 | A | A | 963 | $11.49 | 4,345 | D | — | — | |
| 4 | Common | Class A Common Share | 2022-01-15 | A | A | 1,546 | $9.63 | 5,891 | D | — | — | |
| 5 | Derivative | Restricted Share Unit | 2022-03-16 | M | D | 995 | $0.00 | 2,982 | D | — · — to — | 995 Class A Common Share | (F3) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. (F4) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. |